

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



Am

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/21	A1	(11) International Publication Number: WO 97/41886 (43) International Publication Date: 13 November 1997 (13.11.97)
(21) International Application Number: PCT/IB97/00594 (22) International Filing Date: 5 May 1997 (05.05.97) (30) Priority Data: PN 9765 9 May 1996 (09.05.96) AU (71) Applicant: PHARMA PACIFIC PTY. LTD. [AU/AU]; Bayside Plaza, Suite 6002, 378 Bay Street, Brighton-Le-Sands, NSW 2216 (AU). (72) Inventors: TOVEY, Michael, Gerard; 7, rue Lagrange, F-75005 Paris (FR). KAIDO, Thomas, James; 811 El Carmel Place, San Diego, CA 92109 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: STIMULATION OF HOST DEFENCE MECHANISMS AGAINST TUMORS (57) Abstract A method for treating neoplastic disease in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon administered is less than an amount which induces a pathological response when administered parenterally.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

STIMULATION OF HOST DEFENSE MECHANISMS AGAINST TUMORS

This invention relates to methods of stimulation of host defense
5 mechanisms against pathological conditions in a host mammal by administration of
interferon via the oromucosa. In particular, the invention is applicable to methods of
treatment of neoplastic diseases.

BACKGROUND OF THE INVENTION

Alpha interferons are used widely for the treatment of a variety of
10 hematological malignancies including hairy cell leukemia, chronic myelogenous
leukemia, low grade lymphomas, cutaneous T-cell lymphomas, and solid tumors such
as renal cell carcinoma, melanoma, carcinoid tumors and AIDS-related Kaposi's
sarcoma (Guterman, J.U., *Proc. Natl. Acad. Sci. USA*, 1994 91: 1198-1205).
Antitumor effects are usually seen at high dosage levels, often of the order of tens of
15 millions of units of interferon- α (IFN- α), administered by parenteral injection.
Interferon- α is a Type I interferon, a class which also includes the β and ω
interferons. Although a number of routes of administration, including intravenous,
subcutaneous, intramuscular, topical, and intralesional injection, are commonly
employed for the administration of type I interferons, the oral route has not been
20 generally used, because interferons are proteins which are considered to be inactivated
by proteolytic enzymes and which are not absorbed appreciably in their native form in
the gastrointestinal tract. Indeed a number of studies have failed to detect interferons
in the blood following oral administration (Cantell and Pyh  la, *J. Gen. Virol.*, 1973
20: 97-104; Wills *et al*, *J. IFN Res.*, 1984 4: 399-409; Gilson *et al*, *J. IFN Res.*, 1985
25 5: 403-408).

There have been a number of anecdotal reports of efficacy of low doses
of interferon administered as a nasal spray or as an oral liquid formulation in the
treatment of a variety of conditions, particularly influenza. A series of patent
specifications has described the use of low doses of orally administered interferon of

heterologous species origin for the treatment of infectious rhinotracheitis ("shipping fever") in cattle, and of feline leukemia, and also treatment of other conditions, for enhancement of efficiency of vaccines; for improving the efficiency of food utilization; and for prevention of bovine theileriosis. See U.S. Patent No. 4,462,985, Australian Patent No. 608519, Australian Patent No. 583332 and U.S. Patent No. 5,215,741 respectively. In addition U.S. Patent No. 5,017,371 discloses the use of interferon in this way for treatment of side-effects of cancer chemotherapy or radiotherapy. In these specifications, the interferon used was human interferon- α prepared by the method of Cantell, administered in phosphate buffered saline, at a dose of 0.01 to 5 IU per pound body weight. While these specifications suggest that such low doses of interferon administered to the oropharyngeal mucosa, preferably in a form adapted for prolonged contact with the oral mucosa, may be efficacious for treatment of a wide variety of conditions including cancer, the experimental evidence for conditions other than shipping fever, feline leukemia, canine parvovirus and theileriosis is largely anecdotal. In particular, no properly controlled trials of this treatment in any animal model for human cancers are presented.

In contrast, the invention disclosed herein is based upon the first controlled study in an animal model of the efficacy of oromucosally administered interferon for the treatment of neoplastic diseases.

SUMMARY OF THE INVENTION

This invention provides a method for treating neoplastic disease in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon administered is less than an amount which induces a pathological response when administered parenterally. In particular, the invention provides a method for treating multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumors, cervical cancer, sarcomas including Kaposi's sarcoma, kidney tumors, carcinomas including renal cell carcinoma, hepatic cellular carcinoma,

nasopharyngeal carcinoma, hematological malignancies, colorectal cancer, glioblastoma, laryngeal papillomas, lung cancer, colon cancer, malignant melanoma, and brain tumors including malignant brain tumors. In one embodiment, the method is generally applicable in the treatment of tumors of non-viral etiology.

5 The oromucosal administration may involve administering an effective dose of interferon in a single dose or the effective dose may be administered in a plurality of smaller doses over a period of time sufficient to elicit host defense stimulation equivalent to that of a single dose. Likewise, the effective dose of interferon may be administered continuously over a period of time sufficient to elicit
10 host defense stimulation equivalent to that of a single dose.

 The method may be practiced by administering from about 1500, preferably 5000 IU, to about 20×10^6 IU of interferon, more preferably from about 1×10^4 IU to about 20×10^6 IU of interferon, most preferably from about 1×10^4 to about 1×10^6 IU of interferon, provided that the chosen dose is one which does not induce a
15 parenteral pathological response, as defined herein, or is less than the amount which induces a pathological response when administered parenterally. These dose ranges generally refer to homologous interferon α in man. For another type of interferon the dose that will induce a pathological response may differ from that induced by homologous interferon α in man. A physician treating a patient with a particular type
20 of interferon will be able to readily identify the suitable dose range for the patient to be treated.

 In another embodiment, the invention provides a pharmaceutical composition for oromucosal administration comprising a therapeutically effective amount of at least one interferon. The composition may be provided as a solution,
25 tablet, lozenge, gel, syrup, paste, or controlled release oromucosal delivery system. Optionally, the composition may contain buffers, stabilizers, thickening agents, absorption, and viscosity enhancers, and the like.

 In one embodiment, the pharmaceutical composition is provided in unit dosage form having from about 1500 IU, preferably 5000 IU, to about 20×10^6 IU of

interferon, more preferably from about 1×10^4 IU to about 20×10^6 IU of interferon, most preferably from about 1×10^4 to about 1×10^6 IU of interferon.

The method may be practiced either as the sole therapeutic approach, or as an adjunct to chemo or radiation therapy, or with other cytokines, such as
5 interleukin-2, 12, or 15, or with IFN-inducers.

The method is conducted using a Type I or II interferon, selected from α , β , γ , ω , and consensus interferons, most preferably with a recombinant IFN- α .

DETAILED DESCRIPTION OF THE INVENTION

The invention will now be described in detail by way of reference only
10 using the following definitions and examples. All patents and publications referred to herein are expressly incorporated by reference.

Definitions

As used herein, "interferon" refers to a Type I or Type II interferon, including those commonly designated as α , β , γ , and ω , and mixtures thereof,
15 including the consensus sequence. Interferons are available from a wide variety of commercial sources and are approved for the treatment of numerous indications. The interferon may be from natural sources, but is preferably a recombinant product. For the purposes of the invention, the term "interferon" also includes polypeptide fragments which have interferon activity, and chimeric or mutant forms of interferon
20 in which sequence modifications have been introduced, for example to enhance stability, without affecting the nature of their biological activity, such as disclosed in U.S. Patent Nos. 5,582,824, 5,593,667, and 5,594,107 among others.

Optionally the interferon may be administered concurrently with an inducer of interferon synthesis and release. The inducer may be administered together
25 with the interferon, or may be administered separately. Inducers of interferon include, for example, polynucleotides such as poly I:C; preferably a low molecular weight, orally administrable interferon inducer is used. Suitable inducers are known in the art, for example, Tilorone (U.S. Patent No 3592819; Albrecht *et al*, *J. Med. Chem.* 1974

17: 1150-1156) and the quinolone derivative Imiquimod (Savage *et al*; *Brit. J. Cancer*, 1996 74: 1482-1486).

The methods and compositions of the invention may optionally be used in conjunction with one or more other treatments for the specific condition, and the attending physician or veterinarian will readily be able to select such other treatment as may be appropriate in the circumstances.

In one embodiment, the invention provides a method of treatment of a neoplastic condition in a mammal, comprising the step of administering interferon as described above. The neoplastic condition may be metastatic cancer.

While the method of the invention may be used without concurrent treatment with other agents, it is contemplated that this embodiment of the invention will be particularly useful in the following settings:

- a) as adjuvant therapy, subsequent to surgery, chemotherapy, or radiotherapy given by standard protocols;
- b) for treatment of interferon-sensitive neoplasias, the method of the invention is utilized either alone or in conjunction with conventional chemotherapy or radiotherapy; and
- c) for treatment of interferon-resistant neoplasias, the method of the invention is utilized either alone or most preferably in conjunction with conventional chemotherapy or radiotherapy.

The above methods are directed at inducing and/or maintaining remission of disease. By "in conjunction with other treatment" is meant that the interferon is administered before, during and/or after the radiotherapy or other chemotherapy. The most suitable protocol will depend on a variety of factors, as discussed below.

In particular, it is contemplated that the method of the invention will preferably be used in conjunction with at least one other treatment selected from the group consisting of chemotherapy using cytostatic drugs, one or more other cytokines which have anti-cancer activity but which have a different mechanism of action from

that of interferon, anti-angiogenic agents, and agents which potentiate the activity of interferon. Preferably the second cytokine is interleukin-1 (IL-1), interleukin-2 (IL-2) interleukin-12 (IL-12), or interleukin-15 (IL-15); preferably the angiogenesis inhibitor is AGM-1470 [(Chloroacetyl)-carbamic acid (3R-(3 α , 4 α (2R*, 3R*), 5 β , 6 β))-5-methoxy-4-(2-methyl-3-(3-methoxy-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl ester]; preferably the interferon-potentiating treatment is hyperthermia or arginine butyrate.

Preferred cytostatic drugs to be administered in conjunction with interferon include but are not limited to cyclophosphamide, cisplatin, carboplatin, carmustine (BCNU; N,N-Bis(2-chloroethyl)-N-nitrosourea), methotrexate, adriamycin, α -difluoromethylornithine, and 5-fluorouracil.

The neoplastic conditions susceptible to this method include but are not limited to cancers which respond to parenteral administration of high doses of IFN- α , such as hematological malignancies, e.g. multiple myeloma, hairy cell leukemia, or chronic myelogenous leukemia, low grade lymphomas, cutaneous T cell lymphoma, solid tumors such as renal cell carcinoma and melanoma, carcinoid tumors, or AIDS-associated Kaposi's sarcoma, in particular tumors of non-viral etiology.

In the preparation of the pharmaceutical compositions of this invention, a variety of vehicles and excipients for IFN may be used, as will be apparent to the skilled artisan. Representative formulation technology is taught in, *inter alia*, Remington: The Science and Practice of Pharmacy, 19th ed., Mack Publishing Co., Easton, PA, 1995, and its predecessor editions. The IFN formulation may comprise stability enhancers, such as glycine or alanine, as described in U.S. Patent No. 4,496,537, and/or one or more carriers, such as a carrier protein. For example, for treatment of humans pharmaceutical grade human serum albumin, optionally together with phosphate-buffered saline as diluent, is commonly used. Where the excipient for IFN is human serum albumin, the human serum albumin may be derived from human serum, or may be of recombinant origin. Normally when serum albumin is used it will be of homologous origin.

The IFN may be administered by any means which provides contact of the IFN with the oromucosal cavity of the recipient. Thus it will be clearly understood that the invention is not limited to any particular type of formulation. The present specification describes administration of IFN deep into the oromucosal cavity; this
5 may be achieved with liquids, solids, or aerosols, as well as nasal drops or sprays. Thus the invention includes, but is not limited to, liquid, spray, syrup, lozenges, buccal tablets, and nebuliser formulations. A person skilled in the art will recognize that for aerosol or nebuliser formulations the particle size of the preparation may be important, and will be aware of suitable methods by which particle size may be
10 modified.

In one aspect, the interferon is administered in a single daily dose. Alternatively, the interferon is administered in a plurality of lower doses, distributed over time, so that the net effect is equivalent to the administration of the single higher dose. One approach to this delivery mode is via the provision of a sustained or
15 controlled release device adhered to or implanted in the oromucosal cavity and designed to release interferon over time in an amount equivalent to a single high dose.

Representative formulations of interferon for oromucosal use include the following (all % are w/w):

Tablet: Dextrose BP 45 %; gelatin BP 30 %; wheat starch BP 11%;
20 carmellose sodium BP 5 %; egg albumin BPC 4 %; leucine USP 3 %; propylene glycol BP 2%; and 1×10^6 IU IFN- $\alpha 2$. The tablet may be used as is and allowed to slowly dissolve in the mouth or may be dissolved in water and held in the mouth in contact with the oromucosa as needed.

An interferon paste may be prepared, as described in U.S. Patent No.
25 4,675,184, from glycerin 45%, sodium CMC 2%, citrate buffer (pH 4.5) 25%, distilled water to 100%, and 1×10^6 IU IFN- $\alpha 2$. The interferon paste may be adhered to the buccal mucosa.

Likewise, a gargle or a syrup may be prepared by adding the desired amount of interferon to a commercially available mouthwash or cough syrup formulation.

Within the specific dose ranges referred to above, the optimal treatment
5 in any individual case will depend on the nature of the condition concerned, the stage of disease, previous therapy, other continuing therapy, the general state of health of the mammal, the sensitivity of the subject to interferon, *etc.*, and therefore will be at the physician's or veterinarian's discretion, bearing in mind all these circumstances. The length of treatment will of course vary with the condition being treated, for example,
10 treatment of a slow-growing cancer, such as prostate cancer, would be expected to involve a different course of treatment than treatment of a rapidly growing cancer, such as hepatic cellular carcinoma.

The effective dose disclosed herein is one which does not generate a pathological response in the mammal when administered parenterally. A pathological
15 response may be acute, chronic, or cumulative, and may be manifested by changes in blood chemistry, such as leukopenia, bone marrow depression, or other histological parameters. As used herein, a pathological response includes adverse side effects, such as fever, malaise, or flu-like symptoms, vascular reactions, such as phlebitis, and local inflammatory reactions at the site of injection. Such responses will vary
20 considerably among the patient population in view of individual variations in sensitivity to interferon. A simple test for identifying an acceptable low dose of interferon for oromucosal therapy is to inject the patient with the putative acceptable dose, based upon considerations of age, weight, indication, progression, *etc.* and ascertain if the injection produces a pathological response as defined herein, with local
25 irritation at the site of injection being the most readily ascertainable criterion. If no adverse response is noted, then the same dose may be administered oromucosally. If there is an undesirable response, then the process is repeated at a lower dose, until a non-pathological dose is identified.

For many patients, it is expected that oromucosal doses will be approximately the same as those known to be well tolerated and effective in existing approved parenteral protocols. Therefore, for purposes of specificity, an acceptable low dose of interferon may be from about 1500 IU, preferably 5000 IU, to about 5 20X10⁶ IU of interferon per day. More preferably the dose is from about 1 X 10⁴ IU to about 20 X 10⁶ IU of interferon per day, most preferably from about 1 X 10⁴ IU to about 1 X 10⁶ IU of interferon per day, provided that the dose is one which does not induce a pathological response when administered parenterally. In one embodiment, the total dose may be administered in multiple lower doses over time, or even may be 10 delivered continuously or in a pulsatile manner from a controlled release device adhered to or implanted in the oromucosa.

INTERFERONS AND INTERFERON FORMULATIONS

Mouse IFN- α/β

15 Mouse IFN- α/β (Mu IFN- α/β) was prepared from cultures of C243-3 cells induced with Newcastle disease virus (NDV) and purified as described previously (Tovey *et al*, *Proc. Soc. Exp. Biol. and Med.*, 1974 146: 809-815). The preparation used in this study had a titer of 4 x 10⁶ International Units (IU)/ml and a specific activity of 5 x 10⁷ IU/mg protein as assayed on mouse 929 cells challenged 20 with vesicular stomatitis virus (VSV) as described previously (Tovey *et al*, *Proc. Soc. Exp. Biol. and Med.*, 1974 146: 809-815). The preparation was standardized against the international reference preparation of murine IFN- α/β of the National Institutes of Health (NIH) (G-002-9004-5411).

Human IFN- α -1-8

25 Recombinant human IFN- α 1-8 (Hu IFN- α 1-8; BDBB lot no. CGP 35269-1, Ciba-Geigy, Basel, Switzerland) was prepared and purified as described previously (Meister *et al*, *J. Gen. Virol.*, 1986 67: 1633-1643). The preparation used

in this study had a titer of 70×10^6 IU/ml on homologous human WISH cells challenged with VSV as described previously (Tovey *et al*, *Nature*, 1977 267: 455-457), and a titer on heterologous mouse L929 cells of 1×10^6 IU/ml. The preparation was standardized against both the NIH human IFN- α international reference preparation (G-023-901-527) and the NIH murine IFN- α/β standard (G-002-9004-5411). The specific activity of the IFN preparation was 2×10^8 IU/mg protein.

RECOMBINANT MURINE INTERFERON- α

Recombinant murine interferon- α was purchased from Life Technologies Inc. The preparation used in this study (lot no. HKK404) had a titer of 6×10^6 IU/ml and a specific activity of 6×10^8 IU/mg protein as assayed on mouse L929 cells challenged with VSV (Tovey *et al*, *Proc. Soc. Exp. Biol. Med.*, 1974, 146:406-415).

RECOMBINANT MURINE INTERFERON β

Recombinant murine interferon β was purchased from R & D Systems Inc. The preparation used in this study (lot no. 1976-01S) had a titer of 3.2×10^4 IU/ml and a specific activity of 8×10^6 IU/mg protein as assayed on mouse L929 cells challenged with VSV (Tovey *et al*, *proc. Soc. Exp. Biol. Med.*, 1974, 146:406-415).

RECOMBINANT MURINE INTERFERON γ

Recombinant murine interferon γ was purchased from R & D Systems Inc. The preparation used in this study (2580-03SA) had a titer of 2×10^5 IV/ml and a specific activity of 1×10^7 IU/mg protein as assayed on mouse L929 cells challenged with VSV (Tovey *et al*, *Proc. Soc. Exp. Biol. Med.*, 1974, 146:406-415).

All the interferon preparations were titrated simultaneously in the same assay and standardized against the international reference preparation of murine interferon α/β of the US National Institutes of Health (G-002-9004-5411).

Both murine interferon α/β and recombinant murine interferons were taken up in Ferimmune™ excipient prior to administration.

EXCIPIENT

Interferon preparations were diluted in phosphate buffered saline (PBS) containing bovine serum albumin (BSA). Bovine serum albumin fraction V (RIA grade; immunoglobulin free; Cat. no. A7888; Sigma; USA) was dissolved at a final concentration of 100 $\mu\text{g/ml}$ in PBS (pH 7.4) and sterilized by filtration (0.2 μ , Millex-GV, Millipore, USA).

In the experiments described herein the interferon preparations were diluted in a proprietary excipient. The excipient used was as follows, supplied in the form of tablets (Ferimmune™, Pharma Pacific):

	%w/w	mg/tablet
Dextrose (Glucose) BP**	44.67***	55.84
Gelatin BP**	30.06	37.58
Wheat Starch BP**	11.31	14.14
Carmellose Sodium BP**	4.96	6.20
Egg Albumen BPC**	4.03	5.04
Leucine USP	3.00	3.75
Propylene Glycol BP	1.88	2.35
Dextran 40** (as Dextran 40 Injection BP)	0.06	0.08
Sodium Phosphate BP	0.03	0.04
Sodium Chloride BP	0.01	0.01
Sodium Acid Phosphate BP	0.01	0.01
Total	100.02	125.04

** Calculated on an anhydrous basis

*** Derived from:

	Dextrose (Glucose) BP (anhydrous)	44.64%
5	Glucose BP (as Dextran 40 Injection BP)	0.03%

A single tablet was dissolved in 1.5 ml phosphate buffered saline, centrifuged at 16,000 g for 15 m, and then sterile filtered (0.2 μ , Millex-GV, Millipore, USA), and stored at 4°C prior to use. Excipient was prepared daily prior to use.

INTERFERON DELIVERY SYSTEM

Preliminary experiments showed that the application of 5 μ l of crystal violet to each nostril of a normal adult mouse using a P20 Eppendorf micropipette

resulted in an almost immediate distribution of the dye over the whole surface of the oropharyngeal cavity. Staining of the oropharyngeal cavity was still apparent some 30 minutes after application of the dye. Essentially similar results were obtained using ¹²⁵I-labeled recombinant human IFN- α 1-8 applied in the same manner. This method
5 of administration was therefore used in all subsequent experiments.

For the purposes of the animal experiments described in this specification, it will be clearly understood that the expressions "oromucosal" or "oropharyngeal" or "intranasal/oral" or "intranasal plus oral" or "in/or" with reference to the route of administration of IFN is to be taken to mean administration of the IFN
10 preparation deep into the nasal cavity so that it is rapidly distributed into the oromucosal cavity, i.e. the mouth and throat of the recipient mammal, so as to make contact with the mucosa lining this cavity.

FRIEND ERYTHROLEUKAEMIA CELLS

The IFN- α/β resistant clone, 3C18, of Friend erythroleukaemia cells
15 (FLC) was obtained from Dr E. Affabris, Rome and is described in detail by Affabris *et al*, 1982 (*Virology*, 120: 441-452). These cells were subsequently maintained by *in vivo* passage. Briefly, DBA/2 mice were inoculated by intraperitoneal injection (ip) with approximately 100 LD₅₀ of 3C18 cells and one week later the tumor cells were harvested from the peritoneum of the mice, counted and other mice were again
20 inoculated with 100 LD₅₀ of 3C18 cells. This procedure was repeated for 60 to 100 passages. It has been shown that the 3C18 cells used at the 60th to 100th *in vivo* passage are highly metastatic for the liver and spleen (Gresser *et al*, *Int. J. Cancer*, 1987 39: 789-792). The phenotype of IFN resistance was confirmed routinely by cultivating the *in vivo* passaged cells *in vitro* in the presence of IFN- α/β (Belardelli *et al*, *Int. J. Cancer*, 1982 30: 813-820).
25

The interferon compositions of the present invention are also active against the L1210R6 clone of L1210 lymphoma cells isolated in our laboratory (Gresser *et al.*, 1974, Interferon and cell division. IX. Interferon-resistant L1210 cells

: Characteristics and Origin. J. Nat. Cancer Inst., 52:553-559) and EL4 transplantable tumor derived from mice inoculated with the chemical carcinogen 1-2 dimethyl benzanthrein (Gorer, P.A., 1950, Br. J. Cancer, 4:372-381).

ANIMALS

- 5 The mice used in this study were obtained from a specific pathogen-free colony (IFFA CREDO, France). They were housed in a specific pathogen-free animal facility at the Institut Federatif CNRS at Villejuif according to EEC standards.

INTERFERON BIOASSAY

- 10 Interferon was assayed according to a conventional method. Briefly, samples (20 µl) were diluted in 80 µl of Eagle's Minimal Essential Medium (MEM) (Gibco, France) containing 2% heat-inactivated Fetal Calf Serum (FCS) (Gibco, France) and added to each well of a microtitre plate (Falcon, cat. no. 3072) using a multichannel micro-pipette (Finnpipette, Labsystem, 50-300 µl). WISH or L929 cells (2×10^4 cells/well) were added in 100 µl of MEM containing 2% FCS and incubated
- 15 overnight at 37°C in an atmosphere of 5% CO₂ in air (Forma 3029 CO₂ incubator). The cells were then examined for any signs of toxicity using an Olympus IM GLDW inverted microscope equipped with a 10X objective. Samples which did not exhibit detectable toxicity were then subjected to serial two-fold dilutions starting from an initial 1:10 dilution in a total volume of 200 µl of Eagle's MEM containing 2% FCS,
- 20 by carrying forward 100 µl of diluted material with a multichannel micropipette, in a microplate containing 100 µl per well of fresh Eagle's MEM containing 2% FCS, Appropriate serial two-fold dilutions of the NIH human IFN-α reference standard (G-023-901-527) or the NIH Mu IFN-α/β reference standard (G-002-9004-5411) were also prepared. WISH or L929 cells (2×10^4 cells/well) in 100 µl of Eagle's MEM
- 25 containing 2% FCS were then added to each plate where appropriate and incubated overnight at 37°C in an atmosphere of 5% CO₂ in air. The cell monolayers were then checked for any signs of toxicity and in the absence of any apparent toxicity, the

culture was aspirated and replaced with 200 µl of Eagle's MEM containing 2% FCS containing 100 TCID₅₀ of VSV (2×10^{-4} VSV₂₃ for WISH cells, or 10^{-5} VSV₂₃ for L929 cells). The plates were then incubated overnight at 37°C in an atmosphere of 5% CO₂ in air. The cell monolayers were then examined for specific viral cytopathic effect using an Olympus IM ULWD inverted microscope. Interferon titers were determined from the reciprocal of the dilution which gave 50% protection against specific viral cytopathic effect, and are expressed in international reference units/ml (IU/ml).

Example 1 Anti-Tumor Activity of Oromucosally Administered Interferon-α in Mice Challenged with Friend Erythroleukaemia Cells

In order to establish whether IFN-α administered by the intranasal/oral (in/or) route increases the survival of mice challenged with highly metastatic FLC cells, groups of six 7-8 week-old male DBA/2 mice were challenged intravenously (iv) with 1×10^5 FLC on day 0.

Each group of mice was treated twice a day for 10 consecutive days by the in/or route with either 10^4 IU of a natural mixture of multiple murine IFN-α subtypes (Mu IFN-α) in 10 µl BSA-PBS, or with an equal volume of a mock IFN preparation, which was produced and purified in the same manner as the IFN preparation with the exception of the omission of the virus inducer. The mock IFN preparation did not exhibit detectable IFN activity when assayed in parallel with the purified Mu IFN-α preparation. The results are shown in Table 1.

Table 1

Group	Treatment	Day of Death	Mean day of death ± SE
1	Mock Mu IFN- α	9,9,10,10,10,10	9.6 ± 0.2
2	Mu IFN- α 10 ⁴ IU	28,31,36>100>100	31.7 ± 2.3**

** Calculated for dead animals only

Oromucosal administration of 10⁴ IU of Mu IFN- α twice a day dramatically increased the survival time of mice injected with FLC. In fact 2 of 5 mice were effectively cured as they were alive and well 100 days after challenge with 2 x 10⁴ LD₅₀ of FLC, despite cessation of IFN- α treatment after only 20 days. The results of controlled tests on groups of 10 adult DBA/2 mice infected with 2 X 10⁴ LD₅₀ of FLC and treated oromucosally with 10³ IU of recombinant murine IFN- β or 10³ IU of recombinant murine IFN- γ were similar.

10 Example 2 Larger Trial of Anti-Tumor Activity of Low Dose Oromucosal
Interferon- α in Mice Injected with Friend Erythroleukaemia Cells

In order to confirm the results of Example 1, a larger trial was performed. One hundred fifty 8 week-old female DBA/2 mice were challenged iv with 1 x 10⁵ FLC (2 x 10⁴ FLC LD₅₀) on day 0. Mice were treated with the type and dose of IFN indicated, administered by the in/or route in a 10 μ l volume twice a day for 10 consecutive days. These were 10 mice in each treatment group. The results are

summarized in Table 2.

Table 2

Group	Treatment	Dose	Excipient	Mean day of death \pm SE
1	None	-	None	9.5 \pm 0.2
2	Mock Mu IFN- α	-	BSA/PBS	9.6 \pm 0.2
3	Mu IFN- α	10 ⁴ IU	BSA/PBS	29.4 \pm 25.6 %*
4	Mu IFN- α	10 ³ IU	BSA/PBS	11.6 \pm 0.2
5	Mu IFN- α	10 ² IU	BSA/PBS	10.3 \pm 0.2
6	Hu IFN- α 1-8	10 ⁴ IU	BSA/PBS	18.2 \pm 0.8
7	Hu IFN- α 1-8	10 ³ IU	BSA/PBS	13.1 \pm 0.8
8	HU IFN- α 1-8	10 ² IU	BSA/PBS	11.4 \pm 0.5

IU : International reference units

BSA/PBS : 100 μ g/ml of BSA in PBS pH 7.4

5 Mu IFN- α : natural mixture of murine IFN- α subtypes

Hu IFN- α : single recombinant human IFN- α isotype

* : Some of the animals in this group were still alive at 100 days post treatment

IFN- α administered by the in/or route exhibits a marked anti-tumor activity in mice challenged iv with FLC. Indeed, some IFN-treated mice can be
 10 considered to be cured, as they were still alive more than 100 days after inoculation of 100,000 FLC, in a system in which 4 to 5 FLC cells are sufficient to kill an animal.

Pure preparations of a single recombinant IFN- α subspecies, IFN- α 1-8, a natural mixture of multiple IFN- α subtypes, Mu IFN- α , recombinant murine IFN- β , and recombinant murine IFN- γ exhibit marked anti-tumor activity in this model when
 15 administered by the in/or route, strongly suggesting that the observed anti-tumor activity of oromucosally administered IFN preparations is indeed due to the IFN component of these preparations.

Example 3 Effect of Route of Administration of Interferon on Anti-Tumor Activity

The effect of in/or administered IFN was compared with that of IFN given by conventional routes. Eight week-old female DBA/2 mice were challenged iv with 1×10^5 FLC (2×10^4 FLC LD₅₀) on day 0. Mice were treated twice a day for 10 consecutive days with 10^4 IU of Mu IFN- α (the optimal dose as determined in Example 2) administered by the route indicated. There were 6 mice in each treatment group, and in each case the excipient for the Mu IFN- α was BSA in PBS. The results are summarized in Table 3.

Table 3

Group	Treatment	Route	Mean day of death \pm SE
1	None		9.6 ± 0.2
2	Mu IFN- α	Intranasal/oral	30 ± 25.85 %*
3	Mu IFN- α	Oral	18.5 ± 2.0
4	Mu IFN- α	Gastric	13.5 ± 1.3
5	Mu IFN- α	Subcutaneous	23.5 ± 1.6
6	Mu IFN- α	Intramuscular	23.7 ± 1.8
7	Mu IFN- α	Intravenous	25.0 ± 1.2
8	Mu IFN- α	Intraperitoneal	26.7 ± 4.1

10 IU : international reference units

BSA/PBS : 100 μ g/ml of BSA in PBS pH 7.4

* : Some of the animals in this group were still alive 100 days after inoculation of FLC cells.

15 The oromucosal (or in/or) route of administration is at least as effective as the commonly used parenteral routes, such as iv, intramuscular (im), and subcutaneous (sc) injection, if not more effective. The in/or route was in fact as effective as ip injection, which is considered to be the most effective route in mice challenged iv with FLC. In contrast, administration of the same dose of IFN directly

into the mouth appeared to be less effective than combined intranasal and oral administration, while introduction of IFN directly into the stomach of animals via a tube was considerably less effective.

Example 4 Effect of Oromucosal Interferon on Expression of Cellular Proteins

5 IFN- α is known to induce the expression of a number of cellular proteins following binding of the protein to its cell surface receptor. These proteins are thought to provide a useful marker of IFN action.

We evaluated the effect of IFN- α administered via the in/or route on the expression of three IFN-induced proteins, MHC class I antigens, Ly 6A/E antigen and
10 2'-5'-oligoadenylate synthetase.

Treatment of DBA-2 mice (H-2K^d) with up to 20,000 IU of Mu IFN- α by the in/or route did not significantly increase H-2-K^d expression on peripheral blood lymphocytes, monocytes or granulocytes under conditions where as little as 20 IU of Mu IFN- α given ip markedly increased the expression of H-2-K^d antigens on both
15 peripheral blood monocytes and granulocytes. Indeed, expression on monocytes was slightly suppressed.

Similarly, treatment of mice with up to 20,000 IU of IFN- α via the in/or route had no significant effect on the expression of Ly6 A/E antigens, the expression of which is markedly enhanced on the surface of a variety of lymphoid cells following
20 parenteral treatment with type I IFN (Dumont *et al*; *J. Immunol*, 1986 137: 201-210). Similar results were obtained with 200 or 20,000 IU of either Mu IFN- α or Hu IFN- α 1-8 via the in/or route.

Treatment of either Swiss or DBA/2 mice with as little as 20 IU of Mu IFN- α injected ip resulted in a marked increase in 2'-5'-oligoadenylate synthetase
25 activity in both peripheral blood mononuclear cells and splenocytes. In contrast, in the same experiment treatment of mice with up to 20,000 IU of Mu IFN- α via the in/or route did not significantly increase the expression of 2'-5'-oligoadenylate synthetase activity. Furthermore, treatment with 200 or 20,000 IU of either Mu IFN- α or

Hu IFN- α 1-8 by the in/or route had no significant effect on 2'-5'-oligoadenylate synthetase activity at any of the time points tested up to 10 days after the start of IFN treatment.

Example 5 Bioavailability of Interferon Following Oromucosal Administration

5 In order to examine the bioavailability and pharmacokinetics of IFN, mice, which have the most favorable drug-blood volume ratio for such studies, were treated with a single high dose of recombinant IFN- α labeled to the highest specific radioactivity possible with ^{125}I .

A pure preparation of 70×10^6 IU of Hu IFN- α 1-8 was taken up in
10 1.4 mls of PBS, and iodinated as described by Mogensen *et al*, (*Int. J. Cancer*, 1981 28: 575-582) using a modification of the chloramine-T method described by Hunter and Greenwood (*Nature*, 1962 194: 495-496).

The ^{125}I -labeled Hu IFN- α 1-8 (lot no. CGP35269-1) exhibited a
biological activity of 2×10^7 IU/ml when assayed on human WISH cells challenged
15 with VSV and 1×10^6 IU/ml when assayed on mouse L929 cells challenged with VSV.

Six to seven week-old female Swiss mice were injected iv, ip, or treated
in/or with 2×10^7 IU equivalent to 1×10^6 murine IU of ^{125}I Hu IFN- α 1-8
(1.0369×10^7 cpm/mouse). At the time points indicated, three mice per group were
20 sacrificed, blood was collected, and the volume determined. Kidney, liver, lung, spleen, and stomach/esophagus were harvested, blotted, and weighed to a precision of $\pm 1.0 \mu\text{g}$. The radioactivity of each sample was determined individually using a gamma counter. Whole blood was then separated by centrifugation ($800 \text{ g} \times 10 \text{ min.}$, 4°C), the serum was harvested, counted, and frozen at -80°C . The serum was then
25 assayed for IFN content using a standard bioassay on both human WISH cells and on mouse L929 cells as described above. The radioactive material present in the samples

of serum was then isolated by affinity immunoprecipitation and analyzed by SDS-PAGE.

Very high levels of radioactivity ($> 2 \times 10^6$ cpm/ml) were detected in the peripheral blood of animals 5 min. after injection of 1.0369×10^7 cpm/mouse of ^{125}I -labeled Hu IFN- α 1-8 by iv bolus. The amount of radioactivity present in whole blood then declined progressively at 15 and 30 min. The levels of radioactivity detected in the peripheral blood of animals 5 min. after ip injection of 1.0369×10^7 cpm of ^{125}I Hu IFN- α -1-8 were approximately twenty fold lower than the levels detected following an iv bolus. The levels of radioactivity then increased progressively at 15 and 30 min. post-injection. The levels of radioactivity detected in the blood of animals at 5, 10 or 15 min. after the in/or administration of ^{125}I IFN- α 1-8 were significantly lower than those detected at a given time following ip injection of the same quantity of radiolabelled IFN. For all three routes of administration, higher levels of radioactivity were detected in serum than in whole blood following in/or administration of ^{125}I -labeled IFN- α 1-8. The lower levels of radioactivity detected per ml of whole blood compared with the same volume of serum reflect the effectively larger volume of serum counted after removal of the cellular component of whole blood.

Samples of serum from all the mice in the study were assayed for the presence of biologically active IFN using a standard bioassay, as described above, and showed readily detectable levels of biologically active IFN in the serum of all the animals injected either iv or ip with ^{125}I Hu IFN- α 1-8 at all the time points tested. In contrast, no biologically active IFN was detected in the serum of any of the animals at any of the time points tested following the in/or administration of IFN, in spite of the presence of relatively high levels of radioactivity in the serum of these animals.

In order to determine whether the radioactive material detected in the serum of animals treated with ^{125}I Hu IFN- α 1-8 does indeed represent native IFN, the samples were immunoprecipitated with protein A-G Agarose, in order to precipitate

immunoglobulins present in the samples, treated with an affinity-purified polyclonal anti-IFN- α antibody, and further immunoprecipitated. The samples were then subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) as described above.

- 5 SDS-PAGE analysis of the radioactive material in serum following iv or ip injection of ^{125}I Hu IFN- α 1-8 revealed a single homogenous band migrating with an electrophoretic mobility identical to that of uninjected ^{125}I Hu IFN- α 1-8. The apparent molecular weight of the material was estimated to be approximately 20000 Daltons, which corresponds exactly to the molecular weight of native Hu IFN- α 1-8.
- 10 In contrast, none of the samples of serum from mice treated in/or with ^{125}I IFN- α 1-8 contained any material with an apparent molecular weight similar to that of native IFN, even though an identical quantity of radioactive material was loaded on to each gel.

- The tissue distribution of radiolabelled material revealed very high
- 15 levels of radioactivity in the kidneys, high levels in the liver, lung, and spleen of animals 5 min. after the iv injection of ^{125}I IFN- α 1-8. The level of radioactivity present in each of these four organs was then found to decrease progressively at 15 and 30 min. In contrast, the level of radioactivity in the stomach increased progressively at 15 and 30 min. to reach a level comparable to that present in the
- 20 serum of animals 30 min. after an iv bolus.

- Administration of ^{125}I IFN- α 1-8 by ip injection resulted in peak levels of radioactivity in all the tissues examined within 15 min., followed by a decline at 30 min. Similarly, in/or administration of ^{125}I Hu IFN- α 1-8 resulted in peak levels of radioactivity in all the tissues studied after 15 min. with some decline in the levels of
- 25 radioactivity present at 30 min. The levels of radioactivity present in the stomach/esophagus were an order of magnitude greater than those detected in any other organ following the in/or administration of ^{125}I -labeled IFN- α 1-8, and were markedly higher than the levels present in these tissues following parenteral

administration of the same quantity of radiolabelled Hu IFN- α 1-8 by either the iv or ip routes.

Example 6 Pharmacokinetics of Interferon Following Intranasal/Oral Administration

5 For precise determination of the pharmacokinetics of Hu IFN- α 1-8, mice were treated iv, ip or in/or with 1.0369×10^7 cpm/mouse of ^{125}I -labeled Hu IFN- α 1-8, and the levels of radioactivity present in both whole blood and serum were determined at a series of time points over a 24 hour period.

 The pharmacokinetic profile of ^{125}I -labeled Hu IFN- α 1-8 present in the
10 blood of mice after an iv bolus closely followed a logarithmic clearance curve. This agreed with results of a previous study carried out in mice using a closely related molecule, recombinant human α A/D (Bgl) (Bohoslawed *et al*; *J. IFN Res.*, 1986 6: 207-213). The amount of bioavailable material, calculated from the area under the curve of concentration versus time, was also similar to that for human α A/D. A
15 biphasic time-consuming clearance curve was observed following an iv bolus of ^{125}I IFN- α 1-8, which is characteristic of substances which are cleared through the kidneys, in agreement with the results of Example 4. The pharmacokinetics of ^{125}I -labeled IFN- α 1-8 following ip injection closely resembled those previously reported for IFNs administered im.

20 Readily detectable levels of biologically active IFN were present in the serum of all the animals following either an iv bolus or ip injection of ^{125}I -labeled IFN- α 1-8.

 The Friend erythroleukaemia model constitutes a very severe preclinical test of anti-tumor activity, since FLC are highly malignant and metastasize to both the
25 liver and spleen when injected iv. Indeed, results obtained using this model were the basis for the adoption of parenteral injection of IFN- α for treatment of human cancers. Thus, in all the experiments carried out in this study all the untreated animals and animals treated with control preparations died within 10 to 11 days. Injection of only

4 or 5 FLC cells will kill a mouse if no treatment is given. In contrast, some of the animals treated with murine IFN- α by the oromucosal route are still alive more than 100 days after inoculation of 10^5 FLC, and may be considered to be cured.

Indeed, judging from previous work, IFN- α administered by the oromucosal route appears to be more effective than cyclophosphamide, 5-fluorouracil, or methotrexate administered parenterally, which increase survival time by only a few days in animals injected with FLC (Gresser *et al*, *J. Natl. Cancer Inst.*, 1988 **80**: 126-131). Other drugs, such as cisplatin, vincristine, doxorubicin, bleomycin or etoposide are ineffective against this tumor (Gresser *et al*, *J. Natl. Cancer Inst.*, 1988 **80**: 126-131).

Similarly, IFN- α administered by the oromucosal route appears to be more effective against FLC than other cytokines such as IL-1 β , IL-2 and TNF- α administered systemically, which exhibit very little activity in this model.

Previous work has shown that IFN administered parenterally is one of the most active anti-tumor drugs in this model, and that IFN therapy is effective even when initiated after tumor metastases are already present in the liver (Gresser *et al*, *Intl. J. Cancer*, 1987 **39**: 789-792). The present results show that IFN administration by the oromucosal route is equally, or even more, effective.

Daily injections of IFN- α given together with a single dose of cyclophosphamide markedly increased the survival of lymphoma-bearing AKR mice compared to animals treated with either agent alone, when therapy was started after diagnosis of the lymphoma (Gresser *et al*, *Eur. J. Cancer*, 1978 **14**: 97-99). Successful combination therapy using IFN- α Z β and BCNU, *cis*-DDP (cisplatin), methotrexate, adriamycin, and α -difluoromethyl ornithine has also been reported in various pre-clinical animal tumor models. Combination therapy with 5-fluorouracil (5-FU) and IFN has also been reported to be of benefit in the treatment of metastatic colon cancer in man (Ernstoff *et al*, *Journal of Clinical Oncology*, 1989 **7**: 1764-1765). There are, however, other studies which have reported a decreased anti-tumor activity when IFN therapy was combined with the use of cyclophosphamide (Marquet

et al, *Int. J. Cancer*, 1983 31: 223-226; Lee *et al*, *Biochem. Pharmacol.*, 1984 33: 4339-3443), adriamycin (Blackwill *et al*, *Cancer Res.*, 1984 44: 904-908), or 5-FU (Marquet *et al*, 1985 109: 156-158), *i.e.* precisely the same drugs which have been shown to exert a beneficial effect when used in combination with parenteral IFN therapy. Combinations between IFN and other chemotherapy agents can readily be tested using methods described herein.

Combined interleukin-1 (IL-1) and IFN- α/β therapy results in a synergistic anti-tumor effect in mice injected with FLC (Belardelli *et al*, *Int. J. Cancer*, 1991 49: 274-278). The same treatment also exerts a marked anti-tumor effect against a metastatic variant (p11-R-Eb) of the Eb lymphoma, against which either agent alone is ineffective (Gabriele *et al*, *Invasion Metastasis*, 1993 13: 147-162). Of all the cytokines tested, IL-1 was found to be the most effective when combined with parenteral type I IFN therapy.

Combination therapy with the angiogenesis inhibitor AGM-1470 [(Chloroacetyl)-carbamic acid (3R-(3 α , 4 α (2R*, 3R*), 5 β , 6 β))-5-methoxy-4-(2-methyl-3-(3-methoxy-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl ester] given together with IFN- α/β resulted in a markedly increased anti-tumor effect compared to that observed with either agent alone (Brem *et al*, *J. Pediatric Surgery*, 1993 28: 1253-1257).

It has been shown that hyperthermia enhances the anti-tumor action of IFN- α/β against the Lewis lung carcinoma (Yerushalmi *et al*, *Proc. Soc. Exp. Biol. Med.*, 1982 169: 413-415). Arginine butyrate has also been shown to potentiate the anti-tumor action of IFN- α (Chany and Cerutti, *Int. J. Cancer*, 1982 30: 489-493).

Comparison of the degree of protection obtained when a given type and dose of IFN was administered by the oromucosal route compared to the results obtained following systemic administration (ip injection) showed that parenteral administration of IFN was in some cases marginally more effective, and in other cases no more effective, than oromucosal administration.

The results of the biomarker pilot study show quite clearly that none of the three biomarkers tested (MHC class I antigen, Ly6 A/E antigen, and 2'-5'-oligoadenylate synthetase activity) adequately reflects the very marked antitumoral activity exhibited by IFN- α administered by the oromucosal route.

5 The contrast between the very marked increase in the expression of all three IFN-induced proteins observed in all the experiments undertaken following the ip injection of as little as 20 IU of IFN- α and the absence of any detectable effect following the administration of up to 20,000 IU of IFN- α via the oromucosal route is striking.

10 Although we cannot exclude the possibility that an effect on one or other of the biomarkers would have been observed at an earlier or intermediate time point, this seems to be unlikely, as IFN acts on the transcription of the genes coding for these proteins and thus one would not expect to see an effect on any of these biomarkers until a number of hours after IFN treatment.

15 Again, although we cannot exclude the possibility that a systemic effect on one of the other numerous IFN-induced proteins would have been observed following treatment with IFN- α by the oromucosal route, this seems unlikely, as this would imply differential regulation of the expression of certain IFN-induced genes. It is entirely possible, however, that an effect on an IFN biomarker may be observed
20 locally, for example, in nasal lymphocytes following administration of IFN- α via the oromucosal route.

 In keeping with the absence of a detectable effect on the biomarkers studied, no consistent effect was observed on any of the hematological or blood chemistry parameters monitored during oromucosal IFN therapy, even in animals
25 treated with up to 20,000 IU of IFN- α .

 Readily detectable levels of radiolabelled material were found in both whole blood and serum of animals following oromucosal administration of ¹²⁵I-labeled IFN- α 1-8. These results contrast with the results of previous studies, which failed to detect IFN in the serum of animals even after the oral administration of

large quantities of unlabelled IFN. However, the radioactive material detected in both whole blood and serum following oromucosal administration was biologically inactive. Furthermore, the results of SDS-PAGE analysis showed that this material was of low molecular weight, and most probably reflected the absorption of degradation products following digestion of IFN in the stomach and small intestine. Analysis of the tissue distribution of radiolabelled material following oromucosal administration revealed markedly higher levels of radioactivity in the stomach than in any of the other organs tested. Our results show quite clearly that even though biologically active IFN was not absorbed following oromucosal administration, this treatment does nevertheless exert a statistically significant antitumor activity *in vivo*.

Without wishing to be bound by any proposed mechanism for the observed beneficial effect, our results suggest that oromucosally administered IFN exerts its effects against tumor cells via a presently undefined novel mechanism, which does not involve a direct action of exogenously administered IFN, or the induction of endogenous IFN. This is supported by the absence of detectable levels of circulatory IFN or of the three biomarkers tested. It appears that this mechanism may act at least partly by stimulation of the abundant lymphoid tissue surrounding the nasopharyngeal and oral cavities. Since we have shown that oromucosal IFN is at least comparable in efficacy to systemically administered IFN, our results provide strong support for administration of IFN by the oromucosal route in the treatment of neoplastic disease. This could have important implications for the clinical use of IFN.

It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.

WHAT IS CLAIMED IS:

1. A method for treating a neoplastic condition in a mammal which method comprises administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact, said amount being from about 1500 IU to about 20
5 $\times 10^6$ IU, said amount being less than an amount which induces a pathological response in the mammal when administered parenterally.
2. A method of claim 1 in which the effective dose of interferon is administered in a single dose.
- 10 3. A method of claim 1 in which the effective dose of interferon is administered in a plurality of smaller doses over a period of time sufficient to elicit a therapeutic response equivalent to that of a single dose, without inducing a pathological response.
- 15 4. A method of claim 1 in which the dose of interferon is administered continuously over a period of time sufficient to elicit a therapeutic response equivalent to that of a single dose, without inducing a pathological response.
- 20 5. A method of claim 1 in which the total dose of interferon is from about 5000 IU to about 20×10^6 IU of interferon.
6. A method of claim 1 in which the dose of interferon is from about 1×10^4 IU to about 20×10^6 IU of interferon per day.
- 25 7. A method of claim 1 in which the dose of interferon is from about from about 1×10^4 IU to about 1×10^6 IU of interferon per day.
8. A method of claim 1 further comprising conjunctive radiation or chemotherapy.

9. A method of claim 1 further comprising the administration of other cytokines or interferon inducers.
10. A method of claim 1 wherein the interferon comprises a Type I interferon.
- 5 11. A method of claim 10 wherein the interferon is selected from the group consisting of IFN- α , IFN- β , IFN- ω , consensus IFN, and mixtures thereof.
12. A method of claim 11 wherein the IFN- α comprises recombinant IFN- α .
- 10 13. A method of claim 1 wherein the interferon comprises a Type II interferon.
14. A method of claim 13 wherein the Type II interferon comprises γ -IFN.
- 15 15. A method of claim 1 wherein the neoplastic condition is of non-viral etiology.
16. A method for treating multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumors, kidney tumors, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, hematological malignancies, colorectal cancer, glioblastoma, lung cancer, colon cancer, malignant melanoma, and brain tumors including malignant brain tumors in a mammal which method comprises administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact, said amount being from about 1500 IU to about 20×10^6 IU, said amount being less than an amount which induces a pathological response in the mammal when administered parenterally.
- 20 25 17. A method of claim 16 in which the effective dose of interferon is administered in a single dose.

18. A method of claim 16 in which the effective dose of interferon is administered in a plurality of smaller doses over a period of time sufficient to elicit a therapeutic response equivalent to that of a single dose, without inducing a pathological response.

5

19. A method of claim 16 in which the dose of interferon is administered continuously over a period of time sufficient to elicit a therapeutic response equivalent to that of a single dose, without inducing a pathological response.

10 20. A method of claim 16 in which the total dose of interferon is from about 5000 IU to about 20×10^6 IU of interferon.

21. A method of claim 16 in which the dose of interferon is from about 1×10^4 IU to about 20×10^6 IU of interferon per day.

15

22. A method of claim 16 in which the dose of interferon is from about from about 1×10^4 IU to about 1×10^6 IU of interferon per day.

20 23. A method of claim 16 further comprising conjunctive radiation or chemotherapy.

24. A method of claim 16 further comprising the administration of other cytokines or interferon inducers.

25 25. A method of claim 16 wherein the interferon comprises Type I interferon.

26. A method of claim 25 wherein the interferon is selected from the group consisting of IFN- α , IFN- β , IFN- ω , consensus IFN, and mixtures thereof.

27. A method of claim 26 wherein the IFN- α comprises recombinant IFN- α .

28. A method of claim 16 wherein the interferon comprises Type II interferon.

29. A method of claim 28 wherein the interferon comprises γ interferon.

5

30. The use of interferon in the preparation of a medicament for oromucosal contact to treat a neoplastic condition in a mammal which medicament comprises a therapeutically effective amount of the interferon, said amount being from about 1500 IU to about 20×10^6 IU, said amount being less than an amount which induces a
10 pathological response in the mammal when administered parenterally.

31. The use according to claim 30 wherein said neoplastic condition is multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumor, cervical cancer, sarcomas including
15 Kaposi's sarcoma, kidney tumor, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, nasopharyngeal carcinoma, hematological malignancies, colorectal cancer, glioblastoma, laryngeal papilloma, lung cancer, colon cancer, malignant melanoma, or brain tumors including malignant brain tumor.

20 32. The use according to claim 30 or 31 in which the medicament comprises a single dose of the interferon.

33. The use according to claim 30 or 31 in which the medicament comprises a plurality of smaller doses of the interferon sufficient to elicit a response equivalent to
25 that of a single dose, without inducing a pathological response.

34. The use according to any one of claims 30-33 in which the medicament provides for continuous administration of a dose of interferon over a period of time

sufficient to elicit an anti-neoplastic response equivalent to that of a single dose, without inducing a pathological response.

35. The use according to any one of claims 30-34 in which the medicament
5 comprises another cytokine or an interferon-inducer.
36. The use according to any one of claims 30-35 in which the medicament is adapted to administer from about 1500 IU to about 20×10^6 IU of interferon.
- 10 37. The use according to claim 36 in which the medicament is adapted to administer from about 1×10^4 IU to about 20×10^6 IU of interferon per day.
38. The use according to claim 37 in which the medicament is adapted to administer from about 1×10^4 to about 1×10^6 IU of interferon per day.
- 15 39. The use according to any one of claims 30-38 in which the medicament includes another therapeutic agent for simultaneous, separate or sequential therapy.
40. The use according to claim 39 in which the therapeutic agent is selected from
20 the group consisting of cytostatic, anticancer, and antiangiogenic agents.
41. The use according to any one of claims 30-40 in which the interferon is a Type I interferon.
- 25 42. The use according to claim 41 in which the interferon is selected from the group consisting of IFN- α , IFN- β , IFN- ω , consensus IFN, and mixtures thereof.
43. The use according to claim 42 in which the Type I interferon is IFN- α .

44. The use according to any one of claims 30 to 40 in which the interferon is a Type II interferon.
45. The use according to claim 44 in which the Type II interferon is IFN- γ .
- 5 46. The use according to claim 41 or 44 in which the interferon is recombinant material.
47. The use according to any one of claims 30-46 in which the neoplastic condition
10 is multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumor, kidney tumor, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, hematological malignancies, colorectal cancer, glioblastoma, lung cancer, colon cancer, malignant melanoma, or brain tumors including malignant brain tumor.
- 15 48. Interferon composition to stimulate an anti-neoplastic response in a mammal which comprises a therapeutically effective amount of an interferon adapted for oromucosal contact, said amount being from about 1500 IU to 20×10^6 IU, said amount being less than an amount which induces a pathological response in the
20 mammal when administered parenterally.
49. The composition of claim 48 in unit dosage form comprising from about 5000 IU to about 20×10^6 IU of interferon and a pharmaceutically acceptable carrier.
- 25 50. The composition of claim 49 comprising from about 1×10^4 IU to about 20×10^6 IU of interferon.
51. The composition of claim 50 comprising from about 1×10^4 IU to about 1×10^6 IU of interferon.

52. The composition of claim 48 in which the neoplastic condition is multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumor, cervical cancer, sarcomas including
- 5 Kaposi's sarcoma, kidney tumor, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, nasopharyngeal carcinoma, hematological malignancies, colorectal cancer, glioblastoma, laryngeal papilloma, lung cancer, colon cancer, malignant melanoma, or brain tumors including malignant brain tumor.
- 10 53. The composition of claim 48 or 52 which comprises a single dose of the interferon.
54. The composition of claim 48 or 52 which comprises a plurality of smaller doses of the interferon sufficient to elicit a response equivalent to that of a single dose,
- 15 without inducing a pathological response.
55. The composition of any one of claims 48-54 which provides for continuous administration of a dose of interferon over a period of time sufficient to elicit an anti-neoplastic response equivalent to that of a single dose, without inducing a pathological
- 20 response.
56. The composition of any one of claims 48-55 which comprises another cytokine or an interferon-inducer.
- 25 57. The composition of any one of claims 48-56 which includes another therapeutic agent for simultaneous, separate or sequential therapy.
58. The composition of claim 57 in which the therapeutic agent is selected from the group consisting of cytostatic, anticancer, and antiangiogenic agents.

59. The composition of any one of claims 48-58 in which the interferon is a Type I interferon.
- 5 60. The composition of claim 59 in which the interferon is selected from the group consisting of IFN- α , IFN- β , IFN- ω , consensus IFN, and mixtures thereof.
61. The composition of claim 60 in which the Type I interferon is IFN- α .
- 10 62. The composition of any one of claims 48-58 in which the interferon is a Type II interferon.
63. The composition of claim 62 in which the Type II interferon is IFN- γ .
- 15 64. The composition of claim 59 or 62 in which the interferon is recombinant material.
- 20 65. The composition of any one of claims 48-64 in which the neoplastic condition is multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumor, kidney tumor, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, hematological malignancies, colorectal cancer, glioblastoma, lung cancer, colon cancer, malignant melanoma, or brain tumors including malignant brain tumor.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IB 97/00594

A. CLASSIFICATION OF SUBJECT MATTER		
Int Cl ^B : A61K 38/21		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) See keywords as set out below		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Derwent, Chemical Abstracts. Keywords: Interferon, oral, buccal, mouth, nasal, nose, intranasal, mucosa, mucous, oromucosa		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5286748 A (EBY AG) 15 February 1994 See whole document	48-65
X	US 4605555 A (MITSUNOBU SATO, TOKUSHIMA <u>et al.</u>) 12 August 1986 see whole document	48-65
A	AU 12227/88 A1 (AMARILLO CELL CULTURE COMPANY, INC) 19 May 1988	1-65
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 1 July 1997		Date of mailing of the international search report 26 AUG 1997
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (06) 285 3929		Authorized officer BERNARD NUTT Telephone No.: (06) 283 2491

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 97/00594

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Journal of Infectious Diseases, volume 150, No. 2, August 1984, Tobias C S <u>et al.</u> , "Intranasally Applied Recombinant Leukocyte A Interferon in normal volunteers. II. Determination of Minimal Effective and Tolerable Dose see whole document	48-65
X	The Journal of Infectious Diseases, volume 156, No. 1, July 1987, Hayden F G <u>et al.</u> , "Human Nasal Mucosal Responses to Topically Applied Recombinant Leukocyte A Interferon" see whole document	48-65
X	The Journal of Infectious Diseases, volume 148, No. 3 September 1983, Samo T C <u>et al.</u> , "Efficacy and Tolerance of Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers" see whole document	48-65
X	The Journal of Infectious Diseases, volume 148, No. 5, November 1983, Hayden F G <u>et al.</u> , "Human Tolerance and Histopathologic Effects of Long-Term Administration of Intranasal Interferon- α 2	48-65

Information on patent family members

PCT/IB 97/00594

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	5286748	AU	91620/91	CA	2099670	EP	566638
		WO	9210997				
US	4605555	NONE					
AU	12227/88	AT	102047	CA	1320905	DE	3789239
		DK	3743/88	EP	341258	HK	246/95
		KR	9603377	NO	882983	NZ	222457
		WO	8803411	ZA	8708295	US	5019382